CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 19 enrolled
Drug / intervention
lomitapidedrug
Likely dose
lomitapide 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00943306
NCT00943306Phase 3Completed
CompareCT.gov

A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Lomitapide' (LOMITAPIDE) in Patients With Homozygous Familial Hypercholesterolemia

Aegerion Pharmaceuticals, Inc.·interventional·Posted Jul 22, 2009·Updated Jun 13, 2018

In Brief

A Phase 3 clinical trial evaluating lomitapide for Familial Hypercholesterolemia. Completed, enrolled 19 participants across 10 sites in 4 countries.

Detailed Summary

This was a long term follow on study to assess the continued long term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFamilial Hypercholesterolemia
CountriesCanada, Italy, South Africa, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 22, 2009
Enrollment StartOct 29, 2009
Primary CompletionSep 17, 2012
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.9 years ago

Interventions

lomitapidedrug

5-60 mg po every day